Vijay Pande Discusses Shift to Smaller, Focused Bets After Managing $4B at a16z

Vijay Pande discusses his shift from managing $4 billion at a16z to founding a smaller firm focused on concentrated AI-driven biotech investments. The article highlights challenges in clinical trials and the potential of precision medicine through AI.

Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.

Read original article